Navigation Links
Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
Date:12/17/2010

LOUISVILLE, Colo., Dec. 17, 2010 /PRNewswire/ -- Pier Pharmaceuticals Inc.(formerly known as Steady Sleep Rx Co.), a clinical stage biopharmaceutical company focused on the treatment of sleep related breathing disorders (SRBDs), announced today the appointment of Peter W. Letendre, Pharm.D. as its CEO & President and his election to the Board of Directors.

As CEO and President, Dr. Letendre will be responsible for spearheading the clinical, regulatory, IP and strategic direction of the company. Based on data from a pilot proof of concept (POC) study in patients with obstructive sleep apnea (OSA), Dr. Letendre's initial efforts will be to raise additional capital to continue the clinical development of its lead compound, PP-001 for the treatment of OSA.

"Pete brings a wealth of successful experience across all aspects of the pharmaceutical business," said Ken Cohen, Chairman of the Board of Pier.  "The Board is confident he'll be an outstanding and effective leader as we move forward in the development of our sleep apnea drug candidate and the growth of the company."  

Dr. Letendre is an accomplished pharmaceutical industry executive and leader with over 21 years of a proven track record in commercialization, business strategy and management in both large and developing pharmaceutical and biopharmaceutical companies. Prior to joining Pier Pharmaceuticals, Pete was the President and Founder of Greyhound Pharmaceutical Consulting, Chief Commercial Officer at Replidyne, Inc. and Divisional Vice-President and General Manager of the hypertension and infectious disease franchises at Abbott Laboratories. Before joining Abbott Laboratories in 2002, Pete spent twelve years at SmithKline Beecham/GSK in commercial roles of increasing responsibility and scope in the therapeutic areas of psychiatry, neurology, infectious disease and endocrinology/diabetes. Under Pete's leadership and strategic direction, three of the franchises Pete was responsible for in his career eclipsed $1 Billion in sales.  Pete is also the co-founder of LiquiForm Pharmaceuticals and Calor Therapeutics. In addition to his broad-based experience in the pharmaceutical industry, Pete also enjoyed a distinguished career as a clinician, academician, researcher and educator prior to entering the pharmaceutical industry in 1990.  Pete holds a Bachelor of Science (BS) degree in pharmacy and a Doctor of Pharmacy degree (Pharm.D.) both from the Massachusetts College of Pharmacy and Allied Health Sciences.

"I am thrilled to be given the opportunity to lead Pier Pharmaceuticals as we further develop our lead asset for the treatment of obstructive sleep apnea, a medical condition estimated to occur in 18-20 million Americans.  OSA is associated with significant morbidity for which there is no currently approved pharmacologic option" said Dr. Letendre. "I strongly believe that an effective pharmacologic option for treating OSA will be an exceedingly important addition to the armamentarium of practicing physicians faced with managing this complex syndrome on a daily basis."

About Pier Pharmaceuticals

Pier Pharmaceuticals (formerly known as Steady Sleep Rx Co.) is a venture-backed clinical stage biopharmaceutical company founded in 2007 which is focused on the development and commercialization of products to treat sleep related breathing disorders, notably obstructive sleep apnea with its lead compound in development, PP-001. Institutional investors include IllinoisVENTURES and Origin Ventures. For more information about the company, its management and Board of Directors, please visit www.pierpharmaceuticals.com.


'/>"/>
SOURCE Pier Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):